R Andersen1, T H Borch1, A Draghi2, A Gokuldass2, M A H Rana2, M Pedersen1, M Nielsen1, P Kongsted1, J W Kjeldsen2, M C W Westergaard2, H D Radic2, C A Chamberlain2, L R Hölmich3, H W Hendel4, M S Larsen5, Ö Met1, I M Svane1, M Donia6. 1. Center for Cancer Immune Therapy, Department of Hematology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark; Department of Oncology, University of Copenhagen, Copenhagen, Denmark. 2. Center for Cancer Immune Therapy, Department of Hematology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark. 3. Department of Plastic Surgery, University of Copenhagen, Copenhagen, Denmark. 4. Department of Clinical Physiology and Nuclear Medicine, University of Copenhagen, Copenhagen, Denmark. 5. Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. 6. Center for Cancer Immune Therapy, Department of Hematology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark; Department of Oncology, University of Copenhagen, Copenhagen, Denmark. Electronic address: marco.donia@regionh.dk.
Abstract
Background: Almost half of the patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study, we investigated whether the immune system of patients progressing following CPI treatment was able to generate functional tumor-specific immune responses. Materials and methods: Tumor-infiltrating lymphocytes (TILs) were isolated and expanded from metastatic melanoma lesions which progressed during or after anti-programmed cell death protein 1 (PD)-1 and anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) treatment. Tumor-specific immune responses were assessed with co-culture assays of TILs and autologous tumor cells. Results: TILs from 23 metastases of individual patients could be assessed for T cells recognition of autologous tumor cells. All metastases were progressive on or following anti-PD-1 (23/23, 100%), and the majority also after anti-CTLA-4 (17/23, 74%). Functional antitumor immune responses were detected in 19/23 patients (83%). Both CD8+ (in 18/23 patients, 78%) and CD4+ (in 16/23 patients, 70%) TILs were able to recognize autologous tumors. A large fraction of CD8+ TILs (median 23%, range 1.0%-84%) recognized tumor cells. This is similar to the cohorts of unselected patient populations with metastatic melanoma presented in previous studies. The localization of intratumoral immune infiltrates was heterogeneous among samples. In a phase I/II clinical trial, TILs were administered with lymphodepleting chemotherapy, pegIFNα2b and interleukin-2 to 12 patients with CPI-resistant melanoma. Out of 12 patients who previously failed CPI therapy, treatment with TILs resulted in two partial responses, of which one is ongoing. Conclusions: Tumor-reactive T cells appear to heavily infiltrate the tumor microenvironment of patients who failed previous CPI treatment. These patients can still respond to an infusion of unselected autologous TILs. Our results warrant further testing of novel immune re-activation strategies in melanoma patients who failed multiple CPI therapy.
Background: Almost half of the patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study, we investigated whether the immune system of patients progressing following CPI treatment was able to generate functional tumor-specific immune responses. Materials and methods: Tumor-infiltrating lymphocytes (TILs) were isolated and expanded from metastatic melanoma lesions which progressed during or after anti-programmed cell death protein 1 (PD)-1 and anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) treatment. Tumor-specific immune responses were assessed with co-culture assays of TILs and autologous tumor cells. Results: TILs from 23 metastases of individual patients could be assessed for T cells recognition of autologous tumor cells. All metastases were progressive on or following anti-PD-1 (23/23, 100%), and the majority also after anti-CTLA-4 (17/23, 74%). Functional antitumor immune responses were detected in 19/23 patients (83%). Both CD8+ (in 18/23 patients, 78%) and CD4+ (in 16/23 patients, 70%) TILs were able to recognize autologous tumors. A large fraction of CD8+ TILs (median 23%, range 1.0%-84%) recognized tumor cells. This is similar to the cohorts of unselected patient populations with metastatic melanoma presented in previous studies. The localization of intratumoral immune infiltrates was heterogeneous among samples. In a phase I/II clinical trial, TILs were administered with lymphodepleting chemotherapy, pegIFNα2b and interleukin-2 to 12 patients with CPI-resistant melanoma. Out of 12 patients who previously failed CPI therapy, treatment with TILs resulted in two partial responses, of which one is ongoing. Conclusions: Tumor-reactive T cells appear to heavily infiltrate the tumor microenvironment of patients who failed previous CPI treatment. These patients can still respond to an infusion of unselected autologous TILs. Our results warrant further testing of novel immune re-activation strategies in melanomapatients who failed multiple CPI therapy.
Authors: Mario Presti; Marie Christine Wulff Westergaard; Arianna Draghi; Christopher Aled Chamberlain; Aishwarya Gokuldass; Inge Marie Svane; Marco Donia Journal: Cancer Immunol Immunother Date: 2020-11-09 Impact factor: 6.968
Authors: Samantha J Seitter; Richard M Sherry; James C Yang; Paul F Robbins; Mackenzie L Shindorf; Amy R Copeland; Christine T McGowan; Monica Epstein; Thomas E Shelton; Michelle M Langhan; Zulmarie Franco; David N Danforth; Donald E White; Steven A Rosenberg; Stephanie L Goff Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531
Authors: Manon Pillai; Yizhou Jiang; Paul C Lorigan; Fiona C Thistlethwaite; Martine Thomas; Natalia Kirillova; John S Bridgeman; Gray Kueberuwa; Sunetra Biswas; Peter Velazquez; David Chonzi; Ryan D Guest; Zachary J Roberts; Robert E Hawkins Journal: Am J Cancer Res Date: 2022-08-15 Impact factor: 5.942
Authors: Sarah A E Galloway; Garry Dolton; Meriem Attaf; Aaron Wall; Anna Fuller; Cristina Rius; Valentina Bianchi; Sarah Theaker; Angharad Lloyd; Marine E Caillaud; Inge Marie Svane; Marco Donia; David K Cole; Barbara Szomolay; Pierre Rizkallah; Andrew K Sewell Journal: Front Immunol Date: 2019-03-13 Impact factor: 7.561
Authors: Rosa De Groot; Marleen M Van Loenen; Aurélie Guislain; Benoît P Nicolet; Julian J Freen-Van Heeren; Onno J H M Verhagen; Michel M Van Den Heuvel; Jeroen De Jong; Patrick Burger; C Ellen Van Der Schoot; Robbert M Spaapen; Derk Amsen; John B A G Haanen; Kim Monkhorst; Koen J Hartemink; Monika C Wolkers Journal: Oncoimmunology Date: 2019-08-15 Impact factor: 8.110
Authors: Brett A Schroeder; Ralph Graeme Black; Sydney Spadinger; Shihong Zhang; Karan Kohli; Jianhong Cao; Jose G Mantilla; Ernest U Conrad; Stanley R Riddell; Robin L Jones; Cassian Yee; Seth M Pollack Journal: J Immunother Cancer Date: 2020-04 Impact factor: 13.751